STD Diagnostics Market Size To Reach $16.36 Billion By 2030

STD Diagnostics Market Growth & Trends

The global STD diagnostics market size is expected to reach USD 16.36 billion by 2030, expanding at a CAGR of 7.18% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing disease burden of Sexually Transmitted Disease (STD) and efforts by government & non-profit organizations to increase awareness and encourage regular screenings among the younger population are the key factors augmenting the market growth. According to WHO data, around 374 million new cases of syphilis, gonorrhea, chlamydia, and trichomoniasis are recorded every year globally.

Development and commercialization of advanced products, such as next-generation HIV testing kits and multiplex PCR products, enable physicians to timely diagnose & distinguish a range of STIs and provide appropriate treatment. Seegene, Inc., a South Korea-based diagnostic company, provides a wide portfolio of Allplex, Anyplex, and Seeplex products that detect various causative agents. For instance, Allplex STI/BV Panel Assay can distinguish 28 causative agents in a single test. In April 2022, Seegene, Inc. announced the development of Allplex HPV HR Detection.

Allplex HPV HR Detection is the world’s first commercialized ‘3 Ct’ PCR assay. Seegene is focusing to apply this technology to its entire product chain, including STI, Urinary Tract Infection (UTI), and Respiratory Virus (RV) assays. This strategic technological advancement is expected to provide an additional advantage to the company that can help increase its share in the Sexually Transmitted Disease (STD) diagnostics industry.

The HIV National Strategic Plan is a roadmap for eliminating the human immunodeficiency virus pandemic in the U.S. by 2030. The HIV Plan, which will run from 2021 to 2025, is the country's third five-year national HIV plan in a row, with a 10-year goal of halving new human immunodeficiency virus infections by 90% by 2030. Furthermore, the Viral Hepatitis National Strategic Plan focuses on hepatitis B and C, which are sexually transmitted. In January 2021, the US Department of Health and Human Services (HHS) released a nationwide strategy to address the preventable, substantial public health threats posed by viral hepatitis in the United States. The government's beneficial actions create a favorable atmosphere for the expansion of the STD diagnostics industry.

Companies are engaging in strategic initiatives that aid in the development of new products, and regulatory approvals as well as enhance their STD diagnostics product portfolio. For instance, in August 2020, DiaSorin, Inc. received 510 (k) approval from U.S. FDA for introducing LIAISON XL MUREX anti-HBe. It is used for the diagnosis of HBV infection. This immunoassay product works on the principle of chemiluminescence.

 Request a free sample copy or view report summary: STD Diagnostics Market Report

STD Diagnostics Market Report Highlights

• In 2023, the consumables segment accounted for the largest market share and is anticipated to maintain its position over the forecast period owing to high testing rates for the diagnosis of STDs and the commercialization of several assays

• Based on technology, the molecular diagnostics segment is estimated to grow at the fastest CAGR during the forecast period owing to the increasing use of high-throughput PCR technology and the recommendation of NAAT tests for HIV testing. The development of multiplex PCR tests for the simultaneous detection of multiple pathogens is also expected to contribute to the STD diagnostics industry's growth

• Based on application, the HIV testing segment is expected to dominate the STD diagnostics industry in 2023, due to factors such as the high incidence rate of the disease, increasing product approvals for molecular tests, and favorable government initiatives

• Asia Pacific region is anticipated to experience the fastest growth over the forecast period due to an increase in testing rates for STDS, a rise in disposable income, and high disease prevalence of STD in developing countries

STD Diagnostics Market Segmentation

Grand View Research has segmented the global STD diagnostics market based on product, application, technology, location of testing, and region:

STD Diagnostics Product Outlook (Revenue, USD Million, 2018 - 2030)

• Instruments and Services

• Consumables

• Software

STD Diagnostics Application Outlook (Revenue, USD Million, 2018 - 2030)

• CT/NG testing

• Syphilis testing

• PCR testing

• Non-PCR testing

• Gonorrhea testing

• HSV testing

• PCR testing

• Non-PCR testing

• HPV testing

• HIV testing

• Ureaplasma & Mycoplasma testing

• Trichomonas

• VZV testing

• PCR testing

• Non-PCR testing

• Others

STD Diagnostics Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Immunoassay

• Molecular Diagnostics

• Other

STD Diagnostics Location of Testing Outlook (Revenue, USD Million, 2018 - 2030)

• Laboratory Testing

  • Commercial/Private labs

  • Public Health Labs

• Point of Care Testing

Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • India

  • China

  • Japan

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Argentina

  • Brazil

  • Mexico

• Middle East & Africa

  • Saudi Arabia

  • UAE

  • South Africa

  • Kuwait

List of Key Players in the STD Diagnostics Market

• BD

• F. Hoffmann-La Roche Ltd

• Hologic Inc.

• Abbott

• Cepheid (Danaher)

• Qiagen

• OraSure Technologies, Inc.

• Bio-Rad Laboratories, Inc.

• bioMérieux SA

• Thermo Fisher Scientific, Inc.

• Seegene Inc.

• DiaSorin S.p.A